<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405599</url>
  </required_header>
  <id_info>
    <org_study_id>NPJ5004-01/2011 (HEP)</org_study_id>
    <nct_id>NCT01405599</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects</brief_title>
  <official_title>Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ulimorelin in Subjects With Mild, Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of hepatic impairment on the pharmacokinetics of ulimorelin after a
      single intravenous (IV) dose in order to identify potential patients at risks in terms of
      severity of hepatic dysfunction and to determine whether their dosage should be adjusted.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of ulimorelin</measure>
    <time_frame>15, 30, 45, 60, 75, 90 mins, 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 h post-infusion</time_frame>
    <description>To evaluate the pharmacokinetics of ulimorelin in subjects with mild, moderate and severe hepatic impairment compared with subjects who have normal hepatic function following a single dose administration of ulimorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of ulimorelin</measure>
    <time_frame>15, 30, 45, 60, 75, 90 mins, 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 h post-infusion</time_frame>
    <description>To evaluate the pharmacokinetics of ulimorelin in subjects with mild, moderate and severe hepatic impairment compared with subjects who have normal hepatic function following a single dose administration of ulimorelin</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Digestive System Disorders</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTP class C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTP class B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTP class A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulimorelin</intervention_name>
    <description>Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <other_name>TZP101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main Criteria for Inclusion All Subjects:

          -  Adult male or female subjects age 18 to 75 years (both inclusive)

          -  Able to understand and willing to sign an informed consent form (ICF) and able to
             comply with the study restrictions

          -  Female subjects must be postmenopausal (for at least 1 year and confirmed by serum
             follicle-stimulating hormone (FSH) at screening), surgically sterile, practicing true
             abstinence and/or must be using adequate contraception for the duration of the study
             (e.g. contraceptive implants, injectables, oral contraceptives, and intra-uterine
             device and/or barrier methods (condom/occlusive cap with spermicidal
             foam/gel/film/cream/suppository))

          -  Females of childbearing potential must have a negative pregnancy test at screening and
             Day -1

          -  Weight ≥ 50 kg and ≤ 200 kg

          -  Body mass index (BMI) ≤ 40.0 kg/m2, where BMI (kg/m2) = Body weight (kg)/Height2 (m2)
             Inclusion Criteria Hepatic Impairment Subjects (in addition to the criteria for all
             subjects):

          -  Documented mild, moderate or severe hepatic impairment defined as either Child-Pugh A,
             B or C at screening

          -  Stable hepatic impairment, defined as no clinically significant change in disease
             status within the last 30 days before screening, as documented by the subject's recent
             medical history (e.g., no worsening of clinical signs of hepatic impairment and no
             worsening of total bilirubin or prothrombin time by more than 50%)

          -  Must be on a stable dose of medication and/or treatment regimen at least 2 weeks
             before dosing of study medication

          -  Subjects with a history of substance abuse may be enrolled provided that they have not
             abused drugs or alcohol for at least 6 months preceding the study Inclusion Criteria
             for Healthy Subjects (in addition to criteria for all subjects):

          -  Subjects with normal hepatic function, and liver parameters within normal range unless
             approved by the Sponsor's Medical Representative

          -  Subjects not using prescription drugs or non-prescription drugs, including
             over-the-counter medication, non-routine vitamins and herbal products within 3 weeks
             prior to dosing of investigational product [use of oral contraceptives, diuretics,
             noncardioselective beta-blockers, topically applied medication (eye-/nose-drops and
             creams) and occasional use of metaclopramide, ibuprofen and paracetamol is permitted].
             Use of any other medication has to be discussed and agreed before inclusion of the
             subject with the Medical Monitor and the Sponsor's medical representative

        Exclusion Criteria:

        Criteria for Exclusion All Subjects:

          -  Known or suspected allergy to the trial product or related products

          -  History of multiple and/or severe allergies to drugs or foods or a history of severe
             anaphylactic reaction

          -  Participation in another investigational drug trial within 30 days prior to dosing (or
             5 times the half life of the drug if longer)

          -  Acute illness within 14 days prior to dosing unless mild in severity and approved by
             the Investigator and Sponsor's medical representative

          -  History of drug abuse or positive urine drug screen (if not due to concomitant
             medication) at Screening and/or Day -1

          -  Ingestion of alcohol and caffeine within 24 hours prior to dosing and for the duration
             of the study

          -  Donation of more than 450mL of blood / blood products in the 30 days prior to dosing,
             and/or blood donation in the 30 days prior to dosing

          -  Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies or HIV-1
             antigen according to locally used diagnostic testing

          -  Creatinine clearance &lt;50mL/minute, estimated using serum creatinine with the formula
             [(140 - age in years) × weight in kg]/[(72 × serum creatinine in mg/dL) × 0.85 for
             female subjects]

          -  Consumption of Seville oranges, grapefruit or grapefruit juice, star fruit and exotic
             fruits from 7 days prior to first dose of study medication and for entire duration of
             the study

          -  Clinically significant abnormal haematology, biochemistry, coagulation or urinalysis
             screening tests, as judged by the Investigator other than the abnormal values expected
             considering the underlying disease

          -  Subject with any disease or condition which the Investigator feels would interfere
             with the trial outcome or compliance except for conditions associated with hepatic
             impairment in the group of subjects with compromised hepatic function

          -  Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and
             /or diastolic blood pressure ≥ 105 mmHg)

          -  Use of prescription or over-the-counter medication that is extensively bound to
             α1-acid glycoprotein (AAG) which the Investigator or Sponsor feels would interfere
             with the trial outcome

          -  History of cancer (judged not to be in full remission) or presence of cancer (except
             basal cell skin cancer or squamous cell skin cancer) as judged by the Investigator

          -  Subject who has undergone liver transplantation

          -  Not able or willing to refrain from smoking during the inpatient period

          -  Any condition that would make the subject unsuitable for clinical trial participation
             as judged by the Investigator

        Exclusion Criteria Hepatic Impairment Subjects (in addition to criteria for all subjects):

          -  Any medical or surgical conditions, excluding underlying liver disease, which may
             significantly interfere with the pharmacokinetics of the study drug

          -  Fluctuating or rapidly deteriorating hepatic function

        Exclusion Criteria for Healthy Subjects (in addition to criteria for all subjects):

          -  Subjects with clinically significant illness as judged by the Investigator

          -  Exposure to more than three new chemical entities within 12 months prior to the first
             dosing day

          -  Known acute hepatitis with viral, alcoholic, toxic or autoimmunological aetiology
             within the last 6 months. Positive result to the screening test for Hepatitis B
             antigen or Hepatitis C antibodies according to locally used diagnostic testing

          -  Strenuous exercise within 48 hours prior to dosing and for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Tomas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava, nem.</name>
      <address>
        <city>Bratislava</city>
        <zip>83305</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulimorelin</keyword>
  <keyword>Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

